Ibrexafungerp - SCYNEXIS

Drug Profile

Ibrexafungerp - SCYNEXIS

Alternative Names: MK-3118; SCY-078

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Class Antifungals; Glycosides; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis; Candidiasis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Candidiasis
  • Phase II Aspergillosis; Vulvovaginal candidiasis
  • Preclinical Pneumocystis pneumonia

Most Recent Events

  • 23 Oct 2018 SCYNEXIS announces intention to submit sNDA to US FDA for Vulvovaginal candidiasis (Prevention) in 2021
  • 23 Oct 2018 SCYNEXIS plans to initiate a phase III registration program for Vulvovaginal candidiasis, following an end-of-phase II meeting with the FDA in the fourth quarter of 2018 (PO)
  • 04 Sep 2018 Pharmacodynamics data from preclinical trials in Mycosis presented at the European Society of Clinical Microbiology and Infectious Diseases/American Society for Microbiology (ESCMID/ASM-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top